Prime Medicine Inc. has obtained clearance from the New Zealand authority, Medsafe, for the company’s clinical trial application for PM-577a, an investigational Prime Editor for Wilson’s disease.

Researchers from Rivus Pharmaceuticals Inc. presented preclinical efficacy data on RV‑202, a novel oral mitochondrial uncoupler with activity attributed to adenine nucleotide translocase (ANT) activation, in models of obesity.

Researchers from Confo Therapeutics NV presented the preclinical characterization of CFTX-2034, a selective somatostatin receptor subtype 5 (SSTR5) agonist developed using the company’s proprietary technology platform for the treatment of life-threatening hypoglycemic episodes associated with post-bariatric hypoglycemia (PBH).

Although GLP-1 receptor agonists (GLP-1RAs) have significantly advanced obesity treatment, their limitations underscore the need for new therapies that promote weight loss while preserving muscle and supporting metabolic health. Researchers from Rivus Pharmaceuticals Inc. discussed the discovery and preclinical profile of RV-8451, a potentially first-in-class, oral, nonpeptide GLP-1RA.